460 Stock Overview
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 460 from our risk checks.
Sihuan Pharmaceutical Holdings Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.54 |
| 52 Week High | HK$0.83 |
| 52 Week Low | HK$0.49 |
| Beta | 0.68 |
| 1 Month Change | -3.57% |
| 3 Month Change | -6.90% |
| 1 Year Change | -32.50% |
| 3 Year Change | -82.58% |
| 5 Year Change | -75.00% |
| Change since IPO | -81.28% |
Recent News & Updates
Recent updates
A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05
Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) A Risky Dividend Stock?
Jul 22Shareholder Returns
| 460 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 5.9% | 3.7% | 3.6% |
| 1Y | -32.5% | -17.6% | -10.1% |
Price Volatility
| 460 volatility | |
|---|---|
| 460 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 460 has not had significant price volatility in the past 3 months.
Volatility Over Time: 460's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 2,872 | Weicheng Guo | www.sihuanpharm.com |
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China. It offers drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing.
Sihuan Pharmaceutical Holdings Group Ltd. Fundamentals Summary
| 460 fundamental statistics | |
|---|---|
| Market cap | HK$5.01b |
| Earnings (TTM) | -HK$58.36m |
| Revenue (TTM) | HK$2.01b |
2.5x
P/S Ratio-85.9x
P/E RatioIs 460 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 460 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.86b |
| Cost of Revenue | CN¥564.90m |
| Gross Profit | CN¥1.30b |
| Other Expenses | CN¥1.35b |
| Earnings | -CN¥54.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0058 |
| Gross Margin | 69.64% |
| Net Profit Margin | -2.90% |
| Debt/Equity Ratio | 22.9% |
How did 460 perform over the long term?
See historical performance and comparison